ERAS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Erasca Inc (ERAS) is not a strong buy for a beginner, long-term investor at this moment. While there is potential in its RAS-targeted pipeline and recent analyst upgrades, the company's financials are weak, and the technical indicators do not provide a clear entry signal. Additionally, there are no significant trading trends or congress trading data to support a strong buy decision. The investor may consider monitoring the stock for better entry opportunities or further developments in its clinical pipeline.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 63.773, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 11.387, and resistance is at 13.007. Overall, the technical indicators are mixed, with no strong buy signal.
Analysts have recently raised price targets significantly, reflecting optimism about the company's RAS-targeted pipeline. The potential for a 2030 commercial launch of ERAS-0015 and the large addressable market for KRAS-mutant cancers are positive drivers.
Additionally, the MACD indicates bearish momentum, and there is no significant insider or hedge fund activity to support a strong buy case.
In Q3 2025, revenue remained at $0, net income dropped to -$30.61 million (-1.88% YoY), and EPS was -0.11. Gross margin was 0%. The financials indicate weak performance with no revenue growth.
Analysts have recently upgraded their price targets significantly, with Guggenheim, Mizuho, and Piper Sandler providing optimistic ratings. However, Morgan Stanley remains cautious with an Equal Weight rating, and BofA maintains an Underperform rating.
